LB Pharmaceuticals Inc (LBRX)
NASDAQ: LBRX · Real-Time Price · USD
31.38
-0.43 (-1.35%)
At close: Apr 28, 2026, 4:00 PM EDT
31.38
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:04 PM EDT
LB Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for LB Pharmaceuticals stock have an average target of 46.6, with a low estimate of 34 and a high estimate of 78. The average target predicts an increase of 48.50% from the current stock price of 31.38.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for LB Pharmaceuticals stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $45 | Strong Buy | Initiates | $45 | +43.40% | Apr 27, 2026 |
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $36 | Strong Buy | Initiates | $36 | +14.72% | Apr 10, 2026 |
| Stifel | Stifel | Strong Buy Maintains $35 → $40 | Strong Buy | Maintains | $35 → $40 | +27.47% | Mar 27, 2026 |
| Stifel | Stifel | Strong Buy Maintains $27 → $35 | Strong Buy | Maintains | $27 → $35 | +11.54% | Dec 11, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $78 | Buy | Initiates | $78 | +148.57% | Oct 6, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-4.04
from -3.13
EPS Next Year
-4.20
from -4.04
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -3.68 | -3.78 | ||||||
| Avg | -4.04 | -4.20 | ||||||
| Low | -4.54 | -4.32 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.